The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
|
|---|---|
| Published in |
Frontiers in immunology, June 2018
|
| DOI | 10.3389/fimmu.2018.01357 |
| Pubmed ID | |
| Authors |
Ansu Abu Alex, Saravanan Ganesan, Hamenth Kumar Palani, Nithya Balasundaram, Sachin David, Kavitha M. Lakshmi, Uday P. Kulkarni, P. N. Nisham, Anu Korula, Anup J. Devasia, Nancy Beryl Janet, Aby Abraham, Alok Srivastava, Biju George, Rose Ann Padua, Christine Chomienne, Poonkuzhali Balasubramanian, Vikram Mathews |
| Abstract |
Natural killer cells (NK) contribute significantly to eradication of cancer cells, and there is increased interest in strategies to enhance it's efficacy. Therapeutic agents used in the treatment of cancer can impact the immune system in a quantitative and qualitative manner. In this study, we evaluated the impact of arsenic trioxide (ATO) used in the management of acute promyelocytic leukemia (APL) on NK cell reconstitution and function. In patients with APL treated with single agent ATO, there was a significant delay in the reconstitution of circulating NK cells to reach median normal levels from the time of diagnosis (655 days for NK cells vs 145 and 265 days for T cells and B cells, respectively). In vitro experiments demonstrated that ATO significantly reduced the CD34 hematopoietic stem cell (HSC) differentiation to NK cells. Additional experimental data demonstrate that CD34+ sorted cells when exposed to ATO lead to a significant decrease in the expression of IKZF2, ETS1, and TOX transcription factors involved in NK cell differentiation and maturation. In contrast, exposure of NK cells and leukemic cells to low doses of ATO modulates NK cell receptors and malignant cell ligand profile in a direction that enhances NK cell mediated cytolytic activity. We have demonstrated that NK cytolytic activity toward NB4 cell line when exposed to ATO was significantly higher when compared with controls. We also validated this beneficial effect in a mouse model of APL were the median survival with ATO alone and ATO + NK was 44 days (range: 33-46) vs 54 days (range: 52-75). In conclusion, ATO has a differential quantitative and qualitative effect on NK cell activity. This information can potentially be exploited in the management of leukemia. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 18% |
| Researcher | 3 | 14% |
| Professor | 2 | 9% |
| Student > Master | 2 | 9% |
| Other | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 9 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 23% |
| Biochemistry, Genetics and Molecular Biology | 4 | 18% |
| Chemical Engineering | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Unknown | 10 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2018.
All research outputs
#20,726,252
of 25,461,852 outputs
Outputs from Frontiers in immunology
#24,852
of 31,696 outputs
Outputs of similar age
#266,597
of 342,172 outputs
Outputs of similar age from Frontiers in immunology
#616
of 736 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,696 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,172 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 736 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.